1. Home
  2. SLM vs GKOS Comparison

SLM vs GKOS Comparison

Compare SLM & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLM Corporation

SLM

SLM Corporation

HOLD

Current Price

$19.72

Market Cap

3.8B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$96.44

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLM
GKOS
Founded
1972
1998
Country
United States
United States
Employees
1788
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
6.9B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SLM
GKOS
Price
$19.72
$96.44
Analyst Decision
Buy
Strong Buy
Analyst Count
11
14
Target Price
$32.45
$133.07
AVG Volume (30 Days)
4.7M
678.3K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
2.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$3.17
$23.39
Revenue Next Year
$4.64
$27.46
P/E Ratio
$6.91
N/A
Revenue Growth
N/A
32.33
52 Week Low
$17.77
$73.16
52 Week High
$34.55
$130.23

Technical Indicators

Market Signals
Indicator
SLM
GKOS
Relative Strength Index (RSI) 36.29 28.21
Support Level $17.77 $93.96
Resistance Level $28.57 $97.00
Average True Range (ATR) 1.10 3.77
MACD 0.20 -2.37
Stochastic Oscillator 52.70 1.28

Price Performance

Historical Comparison
SLM
GKOS

About SLM SLM Corporation

SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: